https://scholars.lib.ntu.edu.tw/handle/123456789/638449
標題: | Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia | 作者: | Stein, Eytan M DeAngelo, Daniel J Chromik, Jörg Chatterjee, Manik Bauer, Sebastian CHIA-CHI LIN Suarez, Cristina de Vos, Filip Steeghs, Neeltje Cassier, Philippe A Tai, David Kiladjian, Jean-Jacques Yamamoto, Noboru Mous, Rogier Esteve, Jordi Minami, Hironobu Ferretti, Stephane Guerreiro, Nelson Meille, Christophe Radhakrishnan, Rajkumar Pereira, Bernard Mariconti, Luisa Halilovic, Ensar Fabre, Claire Carpio, Cecilia |
公開日期: | 1-三月-2022 | 卷: | 28 | 期: | 5 | 來源出版物: | Clinical cancer research : an official journal of the American Association for Cancer Research | 摘要: | This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638449 | ISSN: | 10780432 | DOI: | 10.1158/1078-0432.CCR-21-1295 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。